NASDAQ:SPRO - Spero Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spero Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.03 +0.14 (+1.57 %) (As of 01/22/2020 06:13 AM ET) Add Compare Today's Range$8.90Now: $9.03▼$9.3650-Day Range$8.89MA: $10.21▼$11.9452-Week Range$7.96Now: $9.03▼$14.48Volume39,967 shsAverage Volume69,204 shsMarket Capitalization$172.74 millionP/E RatioN/ADividend YieldN/ABeta1.98 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO Previous Symbol CUSIPN/A CIK1701108 Webhttp://www.sperotherapeutics.com/ Phone857-242-1600Debt Debt-to-Equity Ratio0.04 Current Ratio6.90 Quick Ratio6.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.97 million Price / Sales43.51 Cash FlowN/A Price / Cash FlowN/A Book Value$6.73 per share Price / Book1.34Profitability EPS (Most Recent Fiscal Year)($2.60) Net Income$-41,660,000.00 Net Margins-287.11% Return on Equity-43.10% Return on Assets-38.10%Miscellaneous Employees41 Outstanding Shares19,130,000Market Cap$172.74 million Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive SPRO News and Ratings via Email Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SPRO Rates by TradingView Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." How were Spero Therapeutics' earnings last quarter? Spero Therapeutics Inc (NASDAQ:SPRO) released its quarterly earnings results on Monday, November, 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.85) by $0.10. The company had revenue of $4.64 million for the quarter, compared to the consensus estimate of $2.03 million. Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%. View Spero Therapeutics' Earnings History. When is Spero Therapeutics' next earnings date? Spero Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Spero Therapeutics. What price target have analysts set for SPRO? 5 equities research analysts have issued 12-month price targets for Spero Therapeutics' stock. Their forecasts range from $20.00 to $35.00. On average, they expect Spero Therapeutics' share price to reach $27.33 in the next year. This suggests a possible upside of 202.7% from the stock's current price. View Analyst Price Targets for Spero Therapeutics. What is the consensus analysts' recommendation for Spero Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics. What are Wall Street analysts saying about Spero Therapeutics stock? Here are some recent quotes from research analysts about Spero Therapeutics stock: 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (9/12/2019) 2. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value SPR994 (oral carbapenem) – cUTI 62% $22.87 $36.88 Shares outstanding 18,656 S/O as of SPR741 (IV potentiator) – MDR Gram (-) $3.22 $3.22 Current share price $9.23 Discount rate 14.5% SPR720 (oral treatment) – NTM $1.34 $1.34." (8/12/2019) 3. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include pharmacokinetic data from a lead-in cohort of 70 patients in 2H19 for SPR994 in the cUTI patient population, Phase 1 data for 1 data for SPR720." (5/9/2019) Has Spero Therapeutics been receiving favorable news coverage? News stories about SPRO stock have trended somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Spero Therapeutics earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Spero Therapeutics. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 377,500 shares, an increase of 6.2% from the December 15th total of 355,600 shares. Based on an average daily trading volume, of 50,500 shares, the short-interest ratio is presently 7.5 days. Currently, 3.1% of the shares of the stock are short sold. View Spero Therapeutics' Current Options Chain. Who are some of Spero Therapeutics' key competitors? Some companies that are related to Spero Therapeutics include ImmunoGen (IMGN), Omeros (OMER), Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), Axovant Sciences (AXON), Vectura Group (VEGPF), TherapeuticsMD (TXMD), AC Immune (ACIU), Morphic (MORF), Kadmon (KDMN), Kura Oncology (KURA), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and MacroGenics (MGNX). What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Catalyst Pharmaceuticals (CPRX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Rigel Pharmaceuticals (RIGL), Allena Pharmaceuticals (ALNA), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), NovaBay Pharmaceuticals (NBY), Exelixis (EXEL) and Immunomedics (IMMU). Who are Spero Therapeutics' key executives? Spero Therapeutics' management team includes the folowing people: Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)Mr. Joel D. Sendek, CFO, Treasurer & Sec. (Age 52)Ms. Cristina Larkin, Chief Operating Officer (Age 49)Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)Ms. Sharon Klahre, Director of Investor Relations When did Spero Therapeutics IPO? (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Spero Therapeutics' major shareholders? Spero Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Janney Montgomery Scott LLC (0.07%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics. Which major investors are buying Spero Therapeutics stock? SPRO stock was bought by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. View Insider Buying and Selling for Spero Therapeutics. How do I buy shares of Spero Therapeutics? Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $9.03. How big of a company is Spero Therapeutics? Spero Therapeutics has a market capitalization of $172.74 million and generates $3.97 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Spero Therapeutics employs 41 workers across the globe.View Additional Information About Spero Therapeutics. What is Spero Therapeutics' official website? The official website for Spero Therapeutics is http://www.sperotherapeutics.com/. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected] MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 147 (Vote Outperform)Underperform Votes: 136 (Vote Underperform)Total Votes: 283MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2020 by MarketBeat.com StaffFeatured Article: What is the Beige Book?
